DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma

Melanoma Research

Volumn 8, Issue 2, 1998, Pages 145-148

  Buzaid, A C ^a   Ali Osman, F ^a   Akande, N ^a   Grimm, E A ^a   Lee, J J ^a   Bedlkian, A ^a   Eton, O ^a   Papadopoulos, N ^a   Plager, C ^a   Legha, S S ^a   Benjamin, R S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

GST gene; Histological response; Polymerase chain reaction

Indexed keywords

ALPHA2A INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CORRELATION FUNCTION; DNA DAMAGE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 7144253118     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199804000-00007     Document Type: Article

References (11)

1. Anderson C, Buzaid A, Legha S. Systemic treatment for advanced cutaneous melanoma. Oncology 1995; 9: 1149-1158.
2. Legha S, Ring S, Eton O, Plager C, Buzaid A, Papadopoulos N. Durable complete responses (CRs) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-α). Proc Am Soc Clin Oncol 1995; 14: 412.
3. Fichtinger-Schepman A, van Oosterom A, Lohman P, Berends F. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutation Res 1987; 190: 59-62.
4. Poirier M, Reed E, Ozols R, Fasy T, Yuspa S. DNA adducts of cisplatin in nucleated peripheral blood cells and tissues of cancer patients. Prog Exp Tumor Res 1987; 31: 104-113.
5. Reed E, Parker R, Gill I, Bicher A, Dabholkar M, Vionnet J, et al. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 1993; 53: 3694-3699.
6. Reed E, Ozols R, Tarone R, Yuspa S, Poirier M. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84: 5024-5028.
7. Oshita F, Yamamoto N, Fukuda M, Ohe Y, Tamura T, Eguchi K, et al. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. Cancer Res 1995; 55: 2334-2337.
8. Buzaid A, Grimm E, Ali-Osman F, Ring S, Eton O, Papadopoulos N, et al. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res 1994; 4: 327-330.
9. Brandt T, Ali-Osman F. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-π gene in human gioblastoma cells. Toxicol Appl Pharmacol 1997; 143: 22-29.
10. Buzaid A, Legha S, Bedikian A, Eton O, Papadopoulos N, Plager C, et al. Neoadjuvant biochemotherapy in melanoma patients (pts) with local regional metastases (LRM). Proc Am Soc Clin Oncol 1996; 15: 434.
11. Buzaid A, Bedikian A, Eton O, Papadopoulos N, Plager C, Ross M, et al. Importance of major histologic response (MHR) in melanoma patients (pts) with local regional metastases (lrm) receiving neoadjuvant biochemotherapy. Proc Am Soc Clin Oncol 1997; 16: 503a.